Title: The antipsychotic drug deadlock -- causes and solutions

**Abstract**

It has been a matter of debate for more than a decade whether second-generation antipsychotics (SGAs) represent an advantage over first generation compounds (FGAs). Especially the "effectiveness" studies (CATIE, CUtLASS, EUFEST) could not unequivocally confirm the superiority of SGAs over FGAs. It has been even questioned whether there was any progress in schizophrenia drug treatment since the introduction of clozapine. We have recently demonstrated in the multicentre, randomised, double-blind "Neuroleptic Strategy Study" (NeSSy; Gründer et al., 2016) that quality of life was statistically and clinically significantly more improved with SGAs compared to FGAs, when selection of the antipsychotic was individualised for each specific patient. SGAs might represent a significant advantage in terms of quality of life, as judged by patients. Based on ratings of psychopathology by clinicians, however, SGAs did not differ significantly from FGAs. The randomised, placebo-controlled trial in parallel groups is considered the gold standard for the evaluation of novel pharmaceuticals (Stroup et al., 2006), although this trial design does not take into account the marked patient heterogeneity characterizing schizophrenia nor the profound disparity in the pharmacological profile of antipsychotics. We suggest that novel study-designs are needed to take into account marked patient heterogeneity and to allow for establishing individual clinical drug profiles (Schulz et al., 2016). In addition, current clinical endpoints completely ignore the patient perspective (social function, quality of life, subjective well-being), and they are usually obtained in short-term studies, which neglect long-term outcomes. The recent discussion about the potential negative effects of long-term antipsychotic treatment on brain structure and the finding that patients with less antipsychotic exposure might have better outcomes urge for the development of new study designs with very long observation periods and new patient-oriented outcomes. These new protocols have to be developed in close collaboration of academia, regulatory agencies and industry.
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